Auxora (zegocractin) — Interim data
2026
Enrollment is ongoing across an expanded network of trial sites, and we expect to provide a study update in 2026.Source filing
CALC biotech catalysts & pipeline
CALCIMEDICA INC · Data as of 2026-09-08
Upcoming catalysts
Auxora (zegocractin) — Initial data
mid-2027
Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027Source filing
Auxora (zegocractin) — IND submission
mid-2027
CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027.Source filing